Literature DB >> 33436735

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

Mitsuru Watanabe1, Yuri Nakamura1,2,3, Shinya Sato1, Masaaki Niino4, Hikoaki Fukaura5, Masami Tanaka6,7, Hirofumi Ochi8, Takashi Kanda9, Yukio Takeshita9, Takanori Yokota10, Yoichiro Nishida10, Makoto Matsui11, Shigemi Nagayama11, Susumu Kusunoki12, Katsuichi Miyamoto12, Masanori Mizuno13, Izumi Kawachi14,15, Etsuji Saji14, Takashi Ohashi16, Shun Shimohama17, Shin Hisahara17, Kazutoshi Nishiyama18, Takahiro Iizuka18, Yuji Nakatsuji19,20, Tatsusada Okuno19, Kazuhide Ochi21, Akio Suzumura22, Ken Yamamoto23, Yuji Kawano1,24, Shoji Tsuji25, Makoto Hirata26, Ryuichi Sakate26, Tomonori Kimura26, Yuko Shimizu27, Akiko Nagaishi28, Kazumasa Okada29, Fumie Hayashi1, Ayako Sakoda1,2, Katsuhisa Masaki1, Koji Shinoda1, Noriko Isobe1,30, Takuya Matsushita1, Jun-Ichi Kira31,32,33.   

Abstract

HLA genotype-clinical phenotype correlations are not established for multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). We studied HLA-DRB1/DPB1 genotype-phenotype correlations in 528 MS and 165 NMOSD cases using Japan MS/NMOSD Biobank materials. HLA-DRB1*04:05, DRB1*15:01 and DPB1*03:01 correlated with MS susceptibility and DRB1*01:01, DRB1*09:01, DRB1*13:02 and DPB1*04:01 were protective against MS. HLA-DRB1*15:01 was associated with increased optic neuritis and cerebellar involvement and worsened visual and pyramidal functional scale (FS) scores, resulting in higher progression index values. HLA-DRB1*04:05 was associated with younger onset age, high visual FS scores, and a high tendency to develop optic neuritis. HLA-DPB1*03:01 increased brainstem and cerebellar FS scores. By contrast, HLA-DRB1*01:01 decreased spinal cord involvement and sensory FS scores, HLA-DRB1*09:01 decreased annualized relapse rate, brainstem involvement and bowel and bladder FS scores, and HLA-DRB1*13:02 decreased spinal cord and brainstem involvement. In NMOSD, HLA-DRB1*08:02 and DPB1*05:01 were associated with susceptibility and DRB1*09:01 was protective. Multivariable analysis revealed old onset age, long disease duration, and many relapses as independent disability risks in both MS and NMOSD, and HLA-DRB1*15:01 as an independent risk only in MS. Therefore, both susceptibility and protective alleles can influence the clinical manifestations in MS, while such genotype-phenotype correlations are unclear in NMOSD.

Entities:  

Year:  2021        PMID: 33436735      PMCID: PMC7804194          DOI: 10.1038/s41598-020-79833-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  62 in total

Review 1.  Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.

Authors:  Dalia Rotstein; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2019-05       Impact factor: 42.937

2.  Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Authors:  Mitsuru Watanabe; Yuri Nakamura; Zuzanna Michalak; Noriko Isobe; Christian Barro; David Leppert; Takuya Matsushita; Fumie Hayashi; Ryo Yamasaki; Jens Kuhle; Jun-Ichi Kira
Journal:  Neurology       Date:  2019-08-30       Impact factor: 9.910

3.  Worldwide prevalence of neuromyelitis optica spectrum disorders.

Authors:  Masahiro Mori; Satoshi Kuwabara; Friedemann Paul
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-02-07       Impact factor: 10.154

4.  Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

Authors:  Maureen A Mealy; Sarah E Mossburg; Su-Hyun Kim; Silvia Messina; Nadja Borisow; Reydmar Lopez-Gonzalez; Juan Pablo Ospina; Michael Scheel; Anusha K Yeshokumar; Amine Awad; M Isabel Leite; JorgeA Jimenez Arango; Friedemann Paul; Jacqueline Palace; Ho Jin Kim; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2018-12-09       Impact factor: 4.339

5.  Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes.

Authors:  Akiko Nagaishi; Mineo Takagi; Atsushi Umemura; Masami Tanaka; Yoko Kitagawa; Makoto Matsui; Masatoyo Nishizawa; Kenji Sakimura; Keiko Tanaka
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-06-10       Impact factor: 10.154

6.  Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.

Authors:  N Collongues; R Marignier; A Jacob; M I Leite; A Siva; F Paul; H Zephir; G Akman-Demir; L Elsone; S Jarius; C Papeix; K Mutch; S Saip; B Wildemann; J Kitley; R Karabudak; O Aktas; D Kuscu; A Altintas; J Palace; C Confavreux; J De Seze
Journal:  Mult Scler       Date:  2013-12-09       Impact factor: 6.312

7.  HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe.

Authors:  Clara Ballerini; Franca R Guerini; Giovanni Rombolà; Eleonora Rosati; Luca Massacesi; Pasquale Ferrante; Domenico Caputo; Lorenzo Figà Talamanca; Paola Naldi; Maria Liguori; Mehdi Alizadeh; Patricia Momigliano-Richiardi; Sandra D'Alfonso
Journal:  J Neuroimmunol       Date:  2004-05       Impact factor: 3.478

8.  HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia.

Authors:  Jing-Shan Wu; Ian James; Wei Qiu; Alison Castley; Frank T Christiansen; William M Carroll; Frank L Mastaglia; Allan G Kermode
Journal:  J Neuroimmunol       Date:  2009-12-16       Impact factor: 3.478

9.  Multiple sclerosis in Japan appears to be a milder disease compared to the UK.

Authors:  L Piccolo; G Kumar; I Nakashima; T Misu; Y Kong; B Wakerley; S Ryan; A Cavey; K Fujihara; Jacqueline Palace
Journal:  J Neurol       Date:  2015-01-22       Impact factor: 4.849

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  8 in total

Review 1.  Genetics and functional genomics of multiple sclerosis.

Authors:  Woori Kim; Nikolaos A Patsopoulos
Journal:  Semin Immunopathol       Date:  2022-01-12       Impact factor: 9.623

Review 2.  Towards a global view of multiple sclerosis genetics.

Authors:  Huw R Morris; Ruth Dobson; Benjamin Meir Jacobs; Michelle Peter; Gavin Giovannoni; Alastair J Noyce
Journal:  Nat Rev Neurol       Date:  2022-09-08       Impact factor: 44.711

Review 3.  A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Mohammad Taheri
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

Review 4.  Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives.

Authors:  Tzu-Lun Huang; Jia-Kang Wang; Pei-Yao Chang; Yung-Ray Hsu; Cheng-Hung Lin; Kung-Hung Lin; Rong-Kung Tsai
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

Review 5.  Genetics behind Cerebral Disease with Ocular Comorbidity: Finding Parallels between the Brain and Eye Molecular Pathology.

Authors:  Kao-Jung Chang; Hsin-Yu Wu; Aliaksandr A Yarmishyn; Cheng-Yi Li; Yu-Jer Hsiao; Yi-Chun Chi; Tzu-Chen Lo; He-Jhen Dai; Yi-Chiang Yang; Ding-Hao Liu; De-Kuang Hwang; Shih-Jen Chen; Chih-Chien Hsu; Chung-Lan Kao
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

Review 6.  Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease.

Authors:  Joseph A Lopez; Martina Denkova; Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Clin Transl Immunology       Date:  2021-07-26

7.  Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis.

Authors:  Vicente Peris Sempere; Sergio Muñiz-Castrillo; Aditya Ambati; Sophie Binks; Anne-Laurie Pinto; Veronique Rogemond; Sean J Pittock; Divyanshu Dubey; Michael D Geschwind; Jeffrey Marc Gelfand; Sonam Dilwali; Soon-Tae Lee; Julian Knight; Katherine S Elliott; Sarosh Irani; Jérôme Honnorat; Emmanuel Mignot
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-02-03

8.  Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS).

Authors:  Omid Mirmosayyeb; Mahdi Barzegar; Alireza Afshari-Safavi; Nasim Nehzat; Afshin Heidari; Parisa Emami; Vahid Shaygannejad
Journal:  Mult Scler Int       Date:  2021-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.